Back to Search
Start Over
Daratumumab for treatment of blastic plasmacytoid dendritic cell neoplasm. A single-case report
- Source :
- Iversen, K F, Holdgaard, P C, Preiss, B, Nyvold, C G & Plesner, T 2019, ' Daratumumab for treatment of blastic plasmacytoid dendritic cell neoplasm A single-case report ', Haematologica, vol. 104, no. 9, pp. e432-e433 . https://doi.org/10.3324/haematol.2018.214635
- Publication Year :
- 2019
-
Abstract
- Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare malignancy derived from a hematopoietic stem cell. The normal counterpart is a precursor plasmacytoid dendritic cell. In the 2016 World Health Organization classification it is classified as a distinct entity among myeloid neoplasms.[1][
- Subjects :
- Male
Myeloid
Skin Neoplasms
Biopsy
Plasmacytoid dendritic cell
Malignancy
World health
03 medical and health sciences
0302 clinical medicine
hemic and lymphatic diseases
Positron Emission Tomography Computed Tomography
medicine
Humans
Online Only Articles
Aged
Retrospective Studies
Cyanosis
business.industry
Hematopoietic stem cell
Daratumumab
Antibodies, Monoclonal
Hematology
Blastic plasmacytoid dendritic cell neoplasm
Dendritic Cells
medicine.disease
Prognosis
stomatognathic diseases
medicine.anatomical_structure
Treatment Outcome
Immunoglobulin G
Mutation
Cancer research
business
030215 immunology
Subjects
Details
- ISSN :
- 15928721
- Volume :
- 104
- Issue :
- 9
- Database :
- OpenAIRE
- Journal :
- Haematologica
- Accession number :
- edsair.doi.dedup.....ea77655808d4195d7f554c57cf8df712
- Full Text :
- https://doi.org/10.3324/haematol.2018.214635